

Ref: ADL/SE/2024-25/51
August 3, 2024

To,
 Listing/ Compliance Department
BSE Limited
 Phiroze Jeejeebhoy Towers,
 Dalal Street,
 Mumbai – 400 001
BSE CODE: 524348

To,
 Listing/ Compliance Department
National Stock Exchange of India Limited,
 “Exchange Plaza”, Plot No. C/1,
 G Block Bandra - Kurla Complex,
 Bandra (East), Mumbai – 400051
NSE SYMBOL: AARTIDRUGS

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

This is to inform you that the Company has received Show Cause Notice from the CGST & C.Ex. Authority. The requisite information as per Para A of Part A of Schedule III under Regulation 30 of the Listing Regulations is given below:

Name of the Authority	Central Goods and Service Tax & Central Excise (CGST & C.Ex.)
Nature and details of the action(s) taken, initiated or order(s) passed	Issuance of show cause notice for contravention of Rule 96(10) of CGST Rule
Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	August 2, 2024
Details of the violation(s) / contravention(s) committed or alleged to be committed	The Company has received Show Cause Notice for contravention of Rule 96(10) of CGST Rule proposing to demand IGST of Rs. 230.70 Crores along with applicable interest and penalty for FY 2017-18 to FY 2021-22.
Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	The Company will file a reply to the Show Cause Notice before the Adjudicating Authority. A potential demand has been put forth which is subject to outcome of the matter. It is very unlikely that this potential demand will materialize as a claim against the Company and result in liability. Currently, it is difficult to assess the financial impact on the Company till the outcome of the matter from the Adjudicating Authority. The Company will update the Stock exchanges of material development, if any, in the aforesaid matter in future.



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

We will update the exchanges on any further updates.

This is for your information and records.

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE
COMPANY SECRETARY & COMPLIANCE OFFICER
ICSI M. No.: F12932